881415-28-7

Basic information

• Product Name: Benzoic acid, 2-bromo-3-fluoro-5-nitro-
• Synonyms: 2-bromo-3-fluoro-5-nitro benzoic acid
• CAS NO: 881415-28-7
• Molecular Formula: C7H3BrFNO4
• Molecular Weight: 264.008
• Mol File: 881415-28-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-bromo-3-fluoro-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-bromo-3-fluoro-5-nitro-(881415-28-7)
• EPA Substance Registry System: Benzoic acid, 2-bromo-3-fluoro-5-nitro-(881415-28-7)

Safety Data

• Hazardous Substances Data: 881415-28-7(Hazardous Substances Data)

Upstream product

• 132715-69-6 2-bromo-3-fluoro-benzoic acid 

Downstream Products

• 1036389-05-5 5-amino-2-bromo-3-fluorobenzoate methyl ester 
• 1036390-96-1 6-amino-2-bromo-3-fluorobenzoate methyl ester 
• 1036389-07-7 5-amino-2-cyano-3-fluorobenzoate methyl ester 
• 1036389-09-9 6-amino-4-fluoro-isoindoline-1-one 
• 1036389-11-3 C₁₈H₁₇FN₂O₅ 
• 881415-30-1 2-bromo-3-fluoro-5-nitrobenzoate methyl ester 
• 881415-29-8 2-bromo-3-fluoro-6-nitrobenzoate methyl ester 

Relevant articles and documents

CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES

The present invention relates to carboxylic acid aromatic 1,2-cyclopropylamides of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES

Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1,R2,R3,R5,R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.